ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Piramal Boosts Drug Conjugates

by Rick Mullin
August 5, 2013 | APPEARED IN VOLUME 91, ISSUE 31

Piramal Healthcare will invest $2.5 million to upgrade its Grangemouth, Scotland, antibody-drug conjugate (ADC) manufacturing facility from clinical to commercial grade. The move will give the company two commercial-scale manufacturing suites at the site plus preclinical capacity. Commercial batch sizes will range from 1 to 1.5 kg. “Piramal was a pioneer when it came to commercial manufacture of ADCs,” says Aidan Walker, president of formulation services. “Continued growth in the ADC market and customer demand have led to this latest investment.”

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment